Receptor-Guided Alignment-Based Comparative 3D-QSAR Studies of Benzylidene Malonitrile Tyrphostins as EGFR and HER-2 Kinase Inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4657-4668

  Kamath, Shantaram ^a   Buolamwini, John K ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BENZYLIDENE MALONONITRILE TYRPHOSTIN DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; HER 2 KINASE; NITRILE; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING ASSAY; BINDING SITE; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENE OVEREXPRESSION; HYDROGEN BOND; MULTIGENE FAMILY; ONCOGENE NEU; PROGNOSIS; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADENOSINE TRIPHOSPHATE; BENZYLIDENE COMPOUNDS; BINDING SITES; ENZYME INHIBITORS; MODELS, MOLECULAR; NITRILES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0142124197     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030065n     Document Type: Article

References (27)

1. Seymore, L. Novel Anti-Cancer Agents in Development: Exciting Prospects and New Challenges. Cancer Treat. Revs. 1999, 25, 301-312.
2. Buolamwini, J. K. Novel Molecular Targets for Cancer Drug Discovery In The Molecular Basis of Human Cancer; Coleman, W. B.; Tsongalis, G. J., Eds.; Humana Press: Totowa, NJ, 2002; pp 521-540.
3. Adjei, A. A. Blocking Oncogenic Ras Signaling for Cancer Therapy. J. Natl. Cancer Inst. 2001, 93, 1062-1074.
4. Druker, B. J. STI571 (Gleevec) as a Paradigm for Cancer Therapy. Trends Mol. Med. 2002, 8, S14-S18.
5. Fantl, W. J.; Johnson, D. E.; Williams, L. T. Signaling by Receptor Tyrosine Kinases. Annu. Rev. Biochem. 1993, 62, 453-481.
6. Ullrich, A. and Schlessinger, J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1991, 61, 203-212.
7. Kolibaba, K. S.; Druker, B. J. Protein Tyrosine Kinases and Cancer. Biochim. Biophys. Acta 1997, 1333, F217-F248.
8. Aaronson, S. A. Growth Factors and Cancer. Science 1991, 254, 1146-1152.
9. de Bono, J. S.; Rowinsky, E. K. The ErbB Receptor Family: A Therapeutic Target for Cancer. Trends Mol. Med. 2002, 8, S19-S26.
10. Workman, P. The Potential for Molecular Oncology to Define New Drug Targets In New Molecular Targets for Cancer Chemotherapy; Kerr, D. J.; Workman, P., Eds., CRC Press: Boca Raton, FL, 1994; pp 1-44.
11. Sauseville, E. A.; Longo, D. L. Growth Factors and Growth Factor Inhibitors In Cancer Therapeutics: Experimental and Clinical Agents; Teicher, B., Eds., Humana Press: Totowa, NJ, 1994; pp 337-370.
12. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of Chemotherapy Plus a Monoclonal Antibody against HER-2 for Metastatic Breast Cancer that Overexpresses HER-2. N. Engl. J. Med. 2001, 344, 783-792.
13. Kubinyi, H. Eds. 3D QSAR in Drug Design: Theory, Methods and Applications; ESCOM Science Publishers: Leiden, 1993.
14. Zhu, L. L.; Hou, T. J.; Chen, L. R.; Xu, X. J. 3D QSAR Analyses of Novel Tyrosine Kinase Inhibitors Based on Pharmacophore Alignment. J. Chem. Inf. Comput. Sci. 2001, 41, 1032-1040.
15. Cramer, III, R. D.; Patterson, D. E.; Bunce, J. D. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
16. Klebe, G.; Abraham, U.; Mietzner, T. Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict their Biological Activity. J. Med. Chem. 1994, 37, 4130-4146.
17. Gazit, A.; Yaish, P.; Gilon, C.; Levitzki, A. Tyrphostins 1: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors J. Med. Chem. 1989, 32, 2344-2352.
18. Gazit, A.; Osherov, N.; Posner, I.; Yaish, P.; Poradosu, E.; Gilon, C.; Levitzki, A. Tyrphostins 2: Heterocyclic and α-Substituted Benzomalonitrile Tyrphostins as Potent Inhibitors of EGF Receptor and HER-2/neu Tyrosine Kinases. J. Med. Chem. 1991, 34, 1896-1907.
19. Gazit, A.; Osherov, N.; Posner, I.; Bar-Sinai, Gilon, C.; Levitzki, A. Tyrphostins 3: Structure-Activity Relationship Studies of α-Substituted Benzylidene Malonitrile 5-S-Aryltyrphostins. J. Med. Chem. 1993, 36, 3556-3564.
20. Levitzki, A.; Gazit Aviv. Tyrosine Kinase Inhibition: An Approach to Drug Development. Science 1995, 267, 1782-1788.
21. Osherov, N., Gazit, A., Gilon, C. and Levistzki, A. Selective Inhibition of Epidermal Growth Factor and HER-2/Neu Receptors by Tyrphostins. J. Biol. Chem. 1993, 268, 11134-11142.
22. Jones, G.; Willet, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 1997, 267, 727-748.
23. Viswanadhan, V. N.; Ghose, A. K.; Revenkar, G. R.; Robins, R. Atomic and Physichochemical Parameters for Three-Dimensional Structure-Directed Quantitative Structure-Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and their Application for an Automated Superposition of Certain Naturally Occurring Antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
24. Taxler, P., Green, J., Mett, H., Sequin, U., Furet P. Use of a Pharmacophore Model for the Design of EGFR Tyrosine Kinase Inhibitors: Isoflavones and 3-Phenyl-4(1H)-quinolones. J. Med. Chem. 1999, 42, 1018-1026.
25. Pierce, A. C., Sandretto, K. L., Bemis G. W. Kinase Inhibitors and the Case for CH ⋯ O Hydrogen Bonds in Protein-ligand Binding. Proteins: Struct. Funct. Genet. 2001, 49, 567-576.
26. Blencke, S., Ullrich, A., Daub, H. Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors J. Biol. Chem. 2003, 278, 15435-15440.
27. 2! J. Mol. Graphics Modeling 2002, 20, 269-276.